2. Search Result
Search Result
Results for "

aura

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Recombinant Proteins

1

Isotope-Labeled Compounds

11

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114258
    LY3295668
    3 Publications Verification

    AK-01

    		 Aurora Kinase Apoptosis Cancer
    LY3295668 (AK-01) is a highly specific and orally active inhibitor of Aurora-A kinase with a Ki values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 avoids the formation of polyploids related to AurB inhibition. LY3295668 can be used for the study of small cell lung cancer .
    LY3295668
  • HY-10200
    BMS-754807
    Maximum Cited Publications
    14 Publications Verification

    		 IGF-1R Insulin Receptor Endocrinology Cancer
    BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC50=1.8 and 1.7 nM, respectively; Ki=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively .
    BMS-754807
  • HY-123159
    AKI603

    		Aurora Kinase Cancer
    AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells .
    AKI603
  • HY-B1658
    Frovatriptan

    (R)-Frovatriptan; SB 209509; VML 251

    		 5-HT Receptor Neurological Disease
    Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .
    Frovatriptan
  • HY-124288
    PDK1/AurA-IN-1

    		Drug Derivative Others
    PDK1/AurA-IN-1 is an active compound.
    PDK1/AurA-IN-1
  • HY-144307
    Aurora A/PKC-IN-1

    		Aurora Kinase PKC Cancer
    Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC50s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity .
    Aurora A/PKC-IN-1
  • HY-W100186
    Win 47338

    		Aurora Kinase Others
    Win 47338 (compound 14) is a control compound of inhibitors of the mitotic kinase monopolar spindle MPS1 and Aurora kinases (AurA/AurB) (Ki>100 μM) .
    Win 47338
  • HY-RS01266
    AURKA Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Aurora Kinase Others

    AURKA Human Pre-designed siRNA Set A contains three designed siRNAs for AURKA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AURKA Human Pre-designed siRNA Set A
    AURKA Human Pre-designed siRNA Set A
  • HY-B1658S
    Frovatriptan-d3 hydrochloride

    (R)-Frovatriptan-d3 hydrochloride; SB 209509-d3 hydrochloride; VML 251-d3 hydrochloride

    		 5-HT Receptor Neurological Disease
    Frovatriptan-d3 (hydrochloride) is the deuterium labeled Frovatriptan . Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .
    Frovatriptan-d3 hydrochloride
  • HY-114258A
    LY3295668 erbumine

    AK-01 erbumine

    		 Aurora Kinase Apoptosis Cancer
    LY3295668 (AK-01) erbumine is a highly specific and orally active inhibitor of Aurora-A kinase with a Ki values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 erbumine can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 erbumine avoids the formation of polyploids related to AurB inhibition. LY3295668 erbumine can be used for the study of small cell lung cancer .
    LY3295668 erbumine
  • HY-10200R
    BMS-754807 (Standard)

    		Reference Standards IGF-1R Insulin Receptor Endocrinology Cancer
    BMS-754807 (Standard) is the analytical standard of BMS-754807 (HY-10200). This product is intended for research and analytical applications. BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC50=1.8 and 1.7 nM, respectively; Ki=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively .
    BMS-754807 (Standard)
  • HY-125404
    DAPK-IN-1

    		DAPK Cardiovascular Disease Neurological Disease Metabolic Disease
    DAPK-IN-1 (The fifth compound in page 19) is a DAPK1 and DAPK3 inhibitor. DAPK-IN-1 is applicable to research related to cerebral infarction, myocardial infarction and renal failure .
    DAPK-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: